Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
Year: 2009
Type: article
Abstract: Advances in the understanding of the biology of renal cell carcinoma have led to recent approval of several new agents including drugs that target vascular endothelial growth factor. Sunitinib is an oral tyrosine kinase inhibitor which interferes with multiple intracellular tumorogenic pathways, and has demonstrated impressive antitumor activity in phase II and subsequently improvement in progression free survival in phase III renal cancer trials. We review the unique side effects of sunitinib therapy with emphasis on establishing effective patient education for anticipation and early management of therapy-related side effects.
Source: OncoTargets and Therapy
DOI: 10.2147/ott.s4052
Author: Robert Dreicer
Institutions: Cleveland Clinic, Glickman Urological Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,836
OpenAlex ID: W1975291790